Molbio Diagnostics IPO

About Molbio Diagnostics IPO

The public issue of the Molbio Diagnostics IPO, a Mainboard IPO, opens on Monday, August 10, 2026 and closes on Wednesday, August 12, 2026. The allotment of shares will take place on Thursday, August 13, 2026. The credit of shares to the demat account will take place on Thursday, August 13, 2026. The initiation of refunds will take place on Friday, August 14, 2026. The listing of shares will take place on Monday, August 17, 2026. The equity shares offered through the IPO are proposed to be listed on the BSE and the NSE.

The offer consists of both a fresh issue and an offer for sale component. The fresh issue will include 24,80,246 shares aggregating up to ₹200 crore. The offer for sale portion includes 91,66,000 shares aggregating up to ₹740 crore. The total number of shares and aggregate amount are 91,66,000 shares aggregating up to ₹940 crore.

Molbio Diagnostics IPO’s price band is set at ₹768 to ₹807 per share. The lot size for an application is 18 shares. The minimum amount of investment required by a retail individual investor is ₹14,526 (18 shares) based on the upper price.

Molbio Diagnostics is an innovative point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies to diagnose infectious and non-communicable diseases. They have developed their Truenat platform, which is a novel POC polymerase chain reaction (PCR) platform that can operate in resource limited settings since it’s battery operated, facilitating decentralized diagnosis within an hour.

Objectives of Molbio Diagnostics IPO

• Funding capital expenditure towards the setting up of infrastructure for a research and development facility and Center of Excellence which will be operated by their wholly-owned Subsidiary, Bigtec and connected office space for the company, subsidiaries and associates.
  
• Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit.
  
• General corporate purposes.
  

Industry Outlook

In Fiscal 2026, the budget has seen an increase in allocation towards healthcare, compared to previous years, with room for improvement as allocations still slightly lag the targets set in national health policies, and investment in primary healthcare can further enhance overall health outcomes. The diagnostics industry is increasingly recognised as the cornerstone of India’s expanding healthcare sector, propelled by the essential need for accurate diagnosis as the first step in effective healthcare delivery. This market encompasses a wide range of tests and procedures, classified broadly as in vitro diagnosis (pathological tests), which involve tests performed on samples taken from the human body, and in vivo tests (radiology), which involve tests and procedures within the living body to visualise or measure internal body functions and structures. The Indian diagnostics market has shown significant growth between Fiscal 2021 to 2026 and is projected to continue this robust trend through Fiscal 2031.

About Molbio Diagnostics

Molbio Diagnostics is an innovative point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies to diagnose infectious and non-communicable diseases. They have developed their ‘Truenat’ platform, which is a novel POC polymerase chain reaction (PCR) platform that can operate in resource limited settings since it is battery operated, facilitating decentralized diagnosis within an hour. They offer their products globally to public health programs, diagnostic laboratories, and private and public hospitals. Until March 31, 2026, they have sold over 12,500 devices in over 90 countries. They have strong in-house research and development (R&D) capabilities with a focus on designing and developing diagnostic platforms that address clinical needs and can be deployed in POC settings through their wholly-owned Subsidiary, Bigtec Private Limited (Bigtec).

Strengths of Molbio Diagnostics

• Well placed to address unmet demand in a large and growing molecular diagnostic market with gaining credence of point-of-care testing.
• Innovative, R&D focused business.
• Developed and commercialized a novel portable multi-disease point-of-care molecular diagnostics platform.
• Scalable business model with strong entry barriers, high proportion of recurring revenues and a growing suite of tests.
• Strategic collaborations and acquisitions enhancing their capabilities and offerings.
• Management team with deep domain expertise and track record of delivering strong financial performance.

Risks of Molbio Diagnostics

• They derive a portion of their revenues from the sale of their products to the Indian central and state governments, and international aid agencies for their public healthcare programs.
• They derive a portion of their revenues from the sale of diagnostic test kits for tuberculosis (TB).
• They cannot assure that their R&D efforts will result in the successful development and obtaining of government approvals for new tests, which could adversely affect their business, results of operations, and cash flows.
• Their subsidiaries, Prognosys Medical Systems Private Limited, Prognosys Healthcare (India) Private Limited and OptraScan INC, have incurred losses in the past and may incur losses in the future which could have an adverse effect on their business, financial condition, etc.
• Their promoters (certain of whom are also directors) hold equity shares in their company and may be interested in their company’s performance in addition to any remuneration and reimbursement of expenses payable to them.

Anchor Investor Bidding Date

Friday, August 7, 2026

Registrar and Book Running Lead Manager

Registrar Details
Kfin Technologies Ltd.
Email: molbio.ipo@kfintech.com
Phone: 040-79615565

Book Running Lead Managers

• Kotak Mahindra Capital Co.Ltd.
  
• IIFL Capital Services Ltd.
  
• Jefferies India Pvt.Ltd.
  
• Motilal Oswal Investment Advisors Ltd.
  

Molbio Diagnostics Contact Details
Plot No. L-46, Phase II-D, Verna Industrial Area, Verna, Salcete, South Goa, Goa, 403722
Email: investors@molbiodiagnostics.com
Phone: 8326724888

Molbio Diagnostics Business Model

The company earns its revenue through being an innovative point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies to diagnose infectious and non-communicable diseases.

Molbio Diagnostics Growth Trajectory

Molbio Diagnostics’s Total Income for FY26 was ₹1455.17 crore, whereas in FY25 and FY24 it was ₹1027.94 crore and ₹840.66 crore, respectively.

The Profit After Tax for FY26 was ₹164.14 crore, whereas in FY25 and FY24 it was ₹138.58 crore and ₹83.54 crore, respectively.

Their EBITDA for FY26 was ₹328.24 crore, whereas in FY25 and FY24 it was ₹256.64 crore and ₹185.09 crore, respectively.

Molbio Diagnostics Market Position

As of March 31, 2026, Truenat is patented in more than 100 countries for the diagnosis of multiple infectious and non-communicable diseases. As of March 31, 2026, they offer molecular testing for 30 diseases, including tuberculosis (TB), COVID, Hepatitis B and C, Human immunodeficiency virus (HIV), and Human Papillomavirus (HPV) with 43 assays.

As of 31 March 2026, the company’s Total Income, Profit After Tax, and EBITDA were ₹1455.17 crore, ₹164.14 crore, and ₹328.24 crore, respectively.

How to apply for Molbio Diagnostics IPO?

• Step 1: Log in to your Kotak Neo Demat account to access IPO investments. Next, select the current IPO section.
• Step 2: Specify IPO details. Enter the number of lots and the price you wish to apply for.
• Step 3: Enter UPI ID. After entering your UPI ID, click submit. This will place your bid with the exchange.
• Step 4: Mandate Notification. Your UPI app will receive a mandate notification to block funds.
• Step 5: Approve Request. Your funds will be blocked once you approve the mandate request on your UPI.